Scientists who use government money to conduct genomic research will now be required to quickly share the data they gather under a policy announced on Wednesday by the National Institutes of Health.
The data-sharing policy, which will take effect with grants awarded in January, will give agency-financed researchers six months to load any genomic data they collect—from human or nonhuman subjects—into a government-established database or a recognized alternative.
The National Science Foundation (NSF) announced today that it will provide a multi-million dollar grant to create a hub of innovation that unites public and private institutions throughout Southern California, headquartered at and administered by the University of Southern California, the California Institute of Technology (Caltech), and the University of California Los Angeles.
The new center is part of the NSF Innovation Corps, or “I-Corps,” initiative, which is aimed at fostering innovation throughout the U.S. by encouraging the translation of ideas and research beyond the laboratory to create social and economic impact. The announcement cements the position of Southern California as a crucial focal point of technology entrepreneurship in the country.
The Maryland Department of Business and Economic Development says its Maryland Venture Fund has made follow-on investments in two Maryland startups totaling $700,000.
Bethesda-based KoolSpan, a mobile security encryption company, received $400,000. BrainScope, also in Bethesda, got $300,000. BrainScope is developing neurotechnology for quickly assessing traumatic brain injury.
Over $21M in New Funding Available for Bioreactors for Reparative Medicine
Learn more at webinar on September 12, 3 pm ET
The National Heart, Lung, and Blood Institute (NHLBI), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), and the National Center for Advancing Translational Sciences (NCATS) announce a new program that aims to support multidisciplinary small business teams in the development of complex, three-dimensional engineering systems for growing heart, lung, or bone marrow tissue. Ultimately, bioreactor designs should provide the most physiologically relevant environment to promote correct 3-dimensional tissue growth and maintenance, which is also efficient, safe and economical. Such devices should be made commercially available and widely disseminated to researchers for application in the translational setting.
Baltimore is going to be OK, as long as it has its big name medical centers.
That’s the big takeaway from a new report by Moody’s Investors Service that looked at the economic impact large medical and education systems have on the cities where they are based.
Venture capital continued its love affair with biotechnology in the second quarter, with investment in biotech reaching record levels.
Venture capitalists invested $1.84 billion in 122 biotech deals in the period, according to a MoneyTree report released Monday by PricewaterhouseCoopers and the National Venture Capital Association, using Thomson Reuters data.
Funding and Research Opportunities
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
NIH Guide Notices:
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
Emergent BioSolutions is looking to fill a position for a senior scientist position.
If hired, the senior scientist will be responsible for vaccine potency and assay development at Emergent BioSolutions.
Key responsibilities of the position include the design and execution of experimental protocols for developing and qualifying animal-based potency assays, conducting in vitro potency assay development and leading vaccine product stability studies with the company’s Potency Assay Group.
GlaxoSmithKline (GSK) has announced that it will freeze the prices of its vaccines for five years for developing countries that graduate from GAVI Alliance support. By committing to offer GAVI Alliance prices for vaccines against pneumonia, diarrhoea and cervical cancer, GSK will support developing country governments as they transition to financing the full cost of their local vaccination programmes.
Since its formation in 2000, the GAVI Alliance has helped to fund the immunisation of 440 million children in some of the world’s poorest countries. GSK is a long-standing partner of the Alliance and reserves its lowest prices for GAVI-eligible countries, which can be as low as one-tenth of prices in developed countries.
On September 14, 2007, Lorenz Diesbergen, age 44, stepped off a commuter train in downtown Chicago and began his daily walk to work in the Chicago Loop. As he crossed the bridge over the Chicago River, his heart’s normal rhythm suddenly deteriorated into an uncoordinated frenzy of useless fibrillations. He may have managed a few more steps—we don’t know—before he pitched forward and fell face-first onto the sidewalk. Paramedics were on the scene within minutes, but efforts at resuscitation proved futile. He left behind a wife and four children.
